Abstract CT542: Preliminary safety and efficacy results of KN046 in combination with KN026 in patients with locally advanced unresectable or metastatic HER2-positive solid cancer

Jifang Gong(Peking University), Lin Shen(Peking University), Jieer Ying(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiangcai Wang(First Affiliated Hospital of Gannan Medical University), Meili Sun(Jinan Central Hospital), Long Xiao(Macau University of Science and Technology), Yanming Zhang(Xuzhou Medical College), Baohong Guo, Summer Xia(AbbVie (United States)), Mingli Ni(Luoyang Central Hospital Affiliated to Zhengzhou University), Lei Chen(Zhuzhou Central Hospital), Zhixiang Zhuang(Soochow University)
Cancer Research
June 15, 2022
10.1158/1538-7445.am2022-ct542
Cited by 3

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Hepatogastroenterology
|Hepatogastroenterology|2012|1.3k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial
|Nature Medicine|2023|541
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417